Ovarian Cancer Research & News

The latest news about Ovarian Cancer

Watch here for posts about the latest ovarian cancer news.

<< First  < Prev   1   2   3   4   5   Next >  Last >> 
  • March 12, 2014 9:29 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Research for Her™, an Online Clinical Research Registry, Honored With Distinguished National Award

    Los Angeles - Jan. 14, 2014 – Research for Her™, a Cedars-Sinai online medical research database aimed at increasing women's participation in clinical studies, received the 2013 Award for Excellence from the Health Improvement Institute for its user-friendly electronic consent form.

    The Research for Her registry allows women to register for potential participation in clinical trials through an online, verified consent process that is just two pages long and written in nontechnical, easy-to-understand language. In comparison, a typical clinical trial consent form, even for low-risk clinical trials, is a printed document ranging from eight to 15 pages and includes complex medical and legal terminology . . .
    Read full article >>

  • March 10, 2014 11:34 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    PARP inhibitors in ovarian cancer:
    current status and future promise

    • Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston MA 02215

    Clinical investigation of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment has rapidly evolved from observations of single-agent in vitro activity of these agents in BRCA-deficient cancer cells in 2005 to the initiation of multiple phase III studies in 2013. With clinical trial design and treatment of ovarian cancer increasingly based on histological and molecular characteristics, PARP inhibitors are on the horizon of becoming the first biologic agents to be used to treat ovarian cancer based upon pre-selection characteristics of the patient’s cancer.
    Read more on ScienceDirect.com >>


  • February 19, 2014 12:05 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)
    18-Feb-2014

    Contact: Garth Sundem
    garth.sundem@ucdenver.edu
    University of Colorado Denver


    COXEN model picks the best drug for ovarian cancer

    There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched. Read entire article >>


    www.eurekalert.org/pub_releases/2014-02/uocd-cmp021814.php

  • December 04, 2013 1:30 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Canyon Ranch Center for Prevention and Health Promotion

    Canyon Ranch Center for Prevention
    and Health Promotion
    :

    LIvES Study  - Lifestyle Intervention for oVarian cancer Enhanced Survival

    Download flyer PDF:  LIvES Study.pdf

    Sponsor: 

    National Cancer Institute

    Summary: 

    LIvES Study: Lifestyle Intervention for oVarian cancer Enhanced Survival The CRCPHP in partnership with the Arizona Cancer Center and the national Gynecological Oncology Group of the National Cancer Institute has launched the first comprehensive study to investigate the role of a healthy diet and physical activity behavioral intervention on ovarian cancer survival. One in 71 women will be diagnosed with ovarian cancer in their lifetime. Survival continues to be less than optimal and efforts to improve survival through healthy lifestyle have yet to be evaluated. This study will recruit over 1000 ovarian cancer survivors from across the country for a 2-year intervention. Study participants receive important health information to promote study engagement and healthy behavior change. The coaching is delivered via Internet using a new interactive coaching platform developed by the UA Arizona Research Laboratories at the BIO5 Institute. UA students from the College of Public Health and Nutritional Sciences undergo an extensive training program offered by center staff lead, Tracy Crane, a registered dietitian who coordinates this national study. With partnerships it is amazing what can be accomplished!

    See website >>
    http://crcphp.arizona.edu/research/research-projects/lives-study

    Download flyer >> LIvES Study.pdf



  • June 13, 2013 12:00 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Promising New Cancer Drugs Empower the Body’s Own Defense System

    The early success of a new class of cancer drugs, revealed in test results released here over the last several days, has raised hope among the world’s top cancer specialists that they may be on the verge of an important milestone in the fight against the disease.

    The excitement has spread to Wall Street. Shares of Merck and Bristol-Myers Squibb, which are developing such drugs, rose more than 3 percent on Monday after data from their studies was presented over the weekend at the meeting of the American Society of Clinical Oncology.

    The drugs, still generally in early testing, work in an entirely new way, by unleashing the immune system to attack cancer cells much as it attacks bacteria. That could be an alternative to often-debilitating chemotherapy.

    Read entire article >>
  • June 13, 2013 11:55 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    ASCO: Targeted Rx Slows Ovarian Ca Progression

    CHICAGO -- Adding the oral anti-angiogenesis drug pazopanib (Votrient) to standard treatment extended disease-free survival in patients with advanced ovarian cancer by an average of 5.6 months, a phase III study showed.

    The time to progression was a median of 17.9 months among women taking pazopanib versus 12.3 months for those in the placebo arm (HR 0.77; 95% CI 0.64-0.91, P=0.0021), according to Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, and colleagues

    "Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments," du Bois said here at the American Society of Clinical Oncology meeting.


    Read entire article >>

  • June 13, 2013 11:47 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Low Dose Naltrexone: Harnessing the Body's Own Chemistry to Treat Human Ovarian Cancer

    Science Daily
    July 13, 2011

    Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis. This discovery, reported in the July 2011 issue of Experimental Biology and Medicine, provides new insights into the pathogenesis and treatment of ovarian neoplasia, the 4th leading cause of cancer-related mortality among women in the United States.


    Read entire article >>

  • June 13, 2013 11:45 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin

    from: Sage Journals

          • Department of Neural and Behavioral Sciences, The Pennsylvania State University College of Medicine, H109, The Milton S Hershey Medical Center, 500 University Drive, Room C3729, Hershey, PA 17033, USA
          • Corresponding author: Dr Ian S Zagon.

            Abstract

            Ovarian cancer is the leading cause of death from gynecological malignancies. Although initial therapeutic modalities are successful, 65% of these women relapse with only palliative treatments available thereafter. Endogenous opioids repress the proliferation of human ovarian cancer cells in vitro, and do so in a receptor-mediated manner. The present study examined whether modulation of opioid systems by the opioid antagonist naltrexone (NTX), alone or in combination with standard of care therapies (taxol/paclitaxel, cisplatin), alters human ovarian cancer cell proliferation in tissue culture and tumor progression in mice. Administration of NTX for six hours every two days, but not continuously, reduced DNA synthesis and cell replication from vehicle-treated controls in tissue culture. Moreover, brief exposure to NTX in combination with taxol or cisplatin had an enhanced anticancer action.

            Read entire article >>
          1. May 30, 2013 12:04 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

            Ovarian Cancer and Its Insidious Threat

            Angelina Jolie alerted women to the BRCA genetic breast-cancer risk. Lost in the news was another killer.

            As a breast cancer oncologist and a breast cancer survivor, I am very aware of the tough treatment choices women are forced to make when facing this disease. Angelina Jolie performed a useful service with her recent announcement that she had undergone prophylactic double mastectomies after learning that she had a BRCA1 gene abnormality that indicates a propensity for breast cancer. The news shed light on the difficult decisions that hundreds of thousands of women who face a breast cancer diagnosisundefinedincluding my patientsundefinedmake every day to survive this disease or reduce their risk of getting it.

            For those of us in the field, Ms. Jolie's disclosure about her course of treatment provides a great opportunity to educate the public. Unfortunately, the insidious risk of ovarian cancer that these same genetic mutations pose has received far less attentionundefineddespite reports that Ms. Jolie plans to have both of her ovaries removed . . . 

            Read entire article >>


            http://online.wsj.com/article/SB10001424127887323
            475304578499433797136750.html?mod=googlenews
            _wsj#articleTabs%3Darticle


          << First  < Prev   1   2   3   4   5   Next >  Last >> 

          COCA – Colorado Ovarian Cancer Alliance • copyright ©2005-2014
          P.O. Box 9216, Denver, CO  80209 - office: 2465 Sheridan Blvd., Denver, CO 80214
            direct 303.506.7014 ~ toll free 1.800.428.0642 ~ fax 1.866.517.0215  
          info@colo-ovariancancer.org
            
          Colorado Ovarian Cancer Alliance is a 501 (c)(3) organization

          Powered by Wild Apricot Membership Software